Skip to main content

Table 2 Urinary and blood biochemical profiles at baseline, time of hospital admission, and at the time of peak creatine kinase (CK)

From: Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report

 

Baseline (before admission)

At the time of admission

At the time of peak CK

Blood studies

Sodium, mmol/L

135[135–145]

137

134 (L)

Potassium, mmol/L

4.6 [3.6–5.0]

6.2 (H)

3.7

Phosphorus, mg/dL

2.9 [2.4–4.5]

2.4

2.5

Calcium, mg/dL

10 [8.4–10.2]

8.6 (L)

5.7 (L)

Ionized calcium, mg/dL

-- [4.5–5.3]

--

3.4 (L)

Bicarbonate, mmol/L

29 [22–31]

21 (L)

13 (L)

Aspartate aminotransferase, U/L

29 [10–50]

354 (H)

1423 (H)

Alanine aminotransferase, U/L

19 [10–50]

125 (H)

330 (H)

Creatine kinase, IU/L

-- [39–308]

44,476 (H)

105,120 (H)

Lactate dehydrogenase, U/L

-- [135–225]

943 (H)

1135 (H)

Creatinine, mg/dL

1.2 [0.67–1.17]

5.7 (H)

5.2 (H)

eGFR, mL/min/1.73 m2a

59

10 (L)

11 (L)

Urine studies

pH

-- [5.0–6.0]

6

6

Dipstick blood

-- [negative]

Large

Large

Dipstick protein, mg/dL

-- [negative]

100

100

Specific gravity

-- [1.008–1.030]

1.018

1.013

Red blood cells/HPF

-- [0–3/HPF]

15

35

White blood cells/HPF

-- [0–5/HPF]

<1

5

Squamous epithelial cells/HPF

-- [0–5/HPF]

10

<1

Leukocyte esterase

-- [negative]

Negative

Negative

  1. [] = laboratory reference values; (H) = above laboratory reference value; (L) = below laboratory reference value;  --= not measured; aeGFR = estimated glomerular filtration rate by MDRD study equation